Figure 8From: Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity Mosapride bidning to hERG1 pore domain. Top panel: The top-docking pose of mosapride that shows a low hERG PD blocking affinity in the human A2A adenosine receptor. (left) Binding interactions are zoomed and detailed (right). Bottom panel: 2D-ligand interaction map for mosapride binding to the A2A receptor.Back to article page